FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998118001> ?p ?o ?g. }

• W1998118001 endingPage "42" @default.
• W1998118001 startingPage "36" @default.
• W1998118001 abstract "Chronic heart failure (CHF) is an increasingly common cardiovascular disorder. Many patients who have CHF report moderate to marked decreases in the frequency of sexual activity, and up to 75% of patients report erectile dysfunction (ED). There are few controlled clinical data on the efficacy and safety of sildenafil citrate in men who have ED and CHF; thus, we evaluated these parameters in patients who had stable CHF. This was a double-blind, placebo-controlled, flexible-dose study. Men who had ED and stable CHF were randomized to receive sildenafil or placebo for 12 weeks. Primary outcomes were questions 3 and 4 of the International Index of Erectile Function. Secondary outcomes included the 5 functional domains of the International Index of Erectile Function, 2 global efficacy assessment questions, intercourse success rate, the Erectile Dysfunction Inventory of Treatment Satisfaction, and the Life Satisfaction Checklist. By week 12, patients who received sildenafil (n = 60) showed significant improvements on questions 3 and 4 compared with patients who received placebo (n = 72; p <0.002). Larger percentages of patients who received sildenafil reported improved erections (74%) and improved intercourse (68%) compared with patients who received placebo (18% and 16%, respectively). Intercourse success rates were 53% among patients who received sildenafil and 20% among those who received placebo. Patients who received sildenafil were highly satisfied with treatment and their sexual life compared with patients who received placebo. Sixty percent of patients who received sildenafil and 48% of patients who received placebo developed adverse events, including transient headache, facial flushing, respiratory tract infection, and asthenia. The incidence of events related to cardiovascular effects was low. Sildenafil is an effective and well-tolerated management of ED in men who have mild to moderate CHF. Chronic heart failure (CHF) is an increasingly common cardiovascular disorder. Many patients who have CHF report moderate to marked decreases in the frequency of sexual activity, and up to 75% of patients report erectile dysfunction (ED). There are few controlled clinical data on the efficacy and safety of sildenafil citrate in men who have ED and CHF; thus, we evaluated these parameters in patients who had stable CHF. This was a double-blind, placebo-controlled, flexible-dose study. Men who had ED and stable CHF were randomized to receive sildenafil or placebo for 12 weeks. Primary outcomes were questions 3 and 4 of the International Index of Erectile Function. Secondary outcomes included the 5 functional domains of the International Index of Erectile Function, 2 global efficacy assessment questions, intercourse success rate, the Erectile Dysfunction Inventory of Treatment Satisfaction, and the Life Satisfaction Checklist. By week 12, patients who received sildenafil (n = 60) showed significant improvements on questions 3 and 4 compared with patients who received placebo (n = 72; p <0.002). Larger percentages of patients who received sildenafil reported improved erections (74%) and improved intercourse (68%) compared with patients who received placebo (18% and 16%, respectively). Intercourse success rates were 53% among patients who received sildenafil and 20% among those who received placebo. Patients who received sildenafil were highly satisfied with treatment and their sexual life compared with patients who received placebo. Sixty percent of patients who received sildenafil and 48% of patients who received placebo developed adverse events, including transient headache, facial flushing, respiratory tract infection, and asthenia. The incidence of events related to cardiovascular effects was low. Sildenafil is an effective and well-tolerated management of ED in men who have mild to moderate CHF." @default.
• W1998118001 created "2016-06-24" @default.
• W1998118001 creator A5001156301 @default.
• W1998118001 creator A5019113370 @default.
• W1998118001 creator A5024372785 @default.
• W1998118001 creator A5057343846 @default.
• W1998118001 creator A5063740588 @default.
• W1998118001 creator A5086026707 @default.
• W1998118001 creator A5090316229 @default.
• W1998118001 date "2005-01-01" @default.
• W1998118001 modified "2023-10-04" @default.
• W1998118001 title "Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure" @default.
• W1998118001 cites W174236887 @default.
• W1998118001 cites W1967851670 @default.
• W1998118001 cites W1971406218 @default.
• W1998118001 cites W1995725983 @default.
• W1998118001 cites W2006654512 @default.
• W1998118001 cites W2026641917 @default.
• W1998118001 cites W2028249713 @default.
• W1998118001 cites W2034107299 @default.
• W1998118001 cites W2040774455 @default.
• W1998118001 cites W2047184366 @default.
• W1998118001 cites W2062678616 @default.
• W1998118001 cites W2065698759 @default.
• W1998118001 cites W2074408964 @default.
• W1998118001 cites W2074646239 @default.
• W1998118001 cites W2086240335 @default.
• W1998118001 cites W2105851379 @default.
• W1998118001 cites W2125733039 @default.
• W1998118001 cites W2129476741 @default.
• W1998118001 cites W2131925302 @default.
• W1998118001 cites W2145935159 @default.
• W1998118001 cites W2158596999 @default.
• W1998118001 cites W2297358297 @default.
• W1998118001 cites W2338144962 @default.
• W1998118001 cites W33566976 @default.
• W1998118001 doi "https://doi.org/10.1016/j.amjcard.2004.08.060" @default.
• W1998118001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15619391" @default.
• W1998118001 hasPublicationYear "2005" @default.
• W1998118001 type Work @default.
• W1998118001 sameAs 1998118001 @default.
• W1998118001 citedByCount "62" @default.
• W1998118001 countsByYear W19981180012012 @default.
• W1998118001 countsByYear W19981180012013 @default.
• W1998118001 countsByYear W19981180012015 @default.
• W1998118001 countsByYear W19981180012016 @default.
• W1998118001 countsByYear W19981180012017 @default.
• W1998118001 countsByYear W19981180012018 @default.
• W1998118001 countsByYear W19981180012020 @default.
• W1998118001 countsByYear W19981180012022 @default.
• W1998118001 crossrefType "journal-article" @default.
• W1998118001 hasAuthorship W1998118001A5001156301 @default.
• W1998118001 hasAuthorship W1998118001A5019113370 @default.
• W1998118001 hasAuthorship W1998118001A5024372785 @default.
• W1998118001 hasAuthorship W1998118001A5057343846 @default.
• W1998118001 hasAuthorship W1998118001A5063740588 @default.
• W1998118001 hasAuthorship W1998118001A5086026707 @default.
• W1998118001 hasAuthorship W1998118001A5090316229 @default.
• W1998118001 hasConcept C126322002 @default.
• W1998118001 hasConcept C142724271 @default.
• W1998118001 hasConcept C164705383 @default.
• W1998118001 hasConcept C197934379 @default.
• W1998118001 hasConcept C204787440 @default.
• W1998118001 hasConcept C27081682 @default.
• W1998118001 hasConcept C2776768464 @default.
• W1998118001 hasConcept C2778093883 @default.
• W1998118001 hasConcept C2778198053 @default.
• W1998118001 hasConcept C2779929075 @default.
• W1998118001 hasConcept C2780202899 @default.
• W1998118001 hasConcept C2908647359 @default.
• W1998118001 hasConcept C42219234 @default.
• W1998118001 hasConcept C71924100 @default.
• W1998118001 hasConcept C99454951 @default.
• W1998118001 hasConceptScore W1998118001C126322002 @default.
• W1998118001 hasConceptScore W1998118001C142724271 @default.
• W1998118001 hasConceptScore W1998118001C164705383 @default.
• W1998118001 hasConceptScore W1998118001C197934379 @default.
• W1998118001 hasConceptScore W1998118001C204787440 @default.
• W1998118001 hasConceptScore W1998118001C27081682 @default.
• W1998118001 hasConceptScore W1998118001C2776768464 @default.
• W1998118001 hasConceptScore W1998118001C2778093883 @default.
• W1998118001 hasConceptScore W1998118001C2778198053 @default.
• W1998118001 hasConceptScore W1998118001C2779929075 @default.
• W1998118001 hasConceptScore W1998118001C2780202899 @default.
• W1998118001 hasConceptScore W1998118001C2908647359 @default.
• W1998118001 hasConceptScore W1998118001C42219234 @default.
• W1998118001 hasConceptScore W1998118001C71924100 @default.
• W1998118001 hasConceptScore W1998118001C99454951 @default.
• W1998118001 hasIssue "1" @default.
• W1998118001 hasLocation W19981180011 @default.
• W1998118001 hasLocation W19981180012 @default.
• W1998118001 hasOpenAccess W1998118001 @default.
• W1998118001 hasPrimaryLocation W19981180011 @default.
• W1998118001 hasRelatedWork W1971021476 @default.
• W1998118001 hasRelatedWork W1975699209 @default.
• W1998118001 hasRelatedWork W1977040685 @default.
• W1998118001 hasRelatedWork W2037909123 @default.
• W1998118001 hasRelatedWork W2047184366 @default.

• next